

Available online at [www.sciencedirect.com](http://www.sciencedirect.com)

ScienceDirect

journal homepage: [www.e-jds.com](http://www.e-jds.com)

## Review article

# Risk assessment and drug interruption guidelines for dentoalveolar surgery in patients with osteoporosis receiving anti-resorptive therapy

Ling-Ying Wei <sup>a,b</sup>, Ching-Ming Chiu <sup>c</sup>, Sang-Heng Kok <sup>a,d</sup>,  
Hao-Hong Chang <sup>a,d</sup>, Shih-Jung Cheng <sup>a,d</sup>, Hung-Ying Lin <sup>a,d</sup>,  
Wei-Yih Chiu <sup>e</sup>, Jang-Jaer Lee <sup>a,d\*</sup>

<sup>a</sup> Department of Dentistry, School of Dentistry, College of Medicine, National Taiwan University, Taipei, Taiwan

<sup>b</sup> Department of Dentistry, National Taiwan University Hospital, Bei-hu Branch, Taipei, Taiwan

<sup>c</sup> Department of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan

<sup>d</sup> Division of Oral and Maxillofacial Surgery, Department of Dentistry, National Taiwan University Hospital, Taipei, Taiwan

<sup>e</sup> Division of Endocrinology and Metabolism, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

Received 29 January 2025; Final revision received 2 February 2025

Available online 11 February 2025

## KEYWORDS

Anti-resorptive agents;  
Dentoalveolar surgery;  
Drug discontinuation;  
Medication-related osteonecrosis of the jaw (MRONJ);  
Risk assessment

**Abstract** Medication-related osteonecrosis of the jaw (MRONJ) is a rare and challenging complication of anti-resorptive therapy. This review addresses the critical issue of risk management in patients with osteoporosis who require dentoalveolar surgery while undergoing anti-resorptive therapy. Dental practitioners should be aware of these risks; however, they should not refuse treatment based solely on them. This review discusses the risks through five major factors: invasive dentoalveolar surgeries, concomitant oral infection, type of medication, duration of medication, and preoperative drug discontinuation. Additionally, we discussed the local factors associated with dental practices. Our review underscored the importance of personalized risk assessment, considering each patient's unique drug history and oral condition. Based on a comprehensive literature review and clinical evidence, we proposed specific guidelines for preoperative drug interruption tailored to different anti-resorptive agents. These recommendations aimed to balance osteoporosis management by minimizing the risk of MRONJ during oral surgical interventions and bridging the knowledge gap in managing patients with osteoporosis requiring dental care. This review will allow

\* Corresponding author. Department of Dentistry, School of Dentistry, College of Medicine, National Taiwan University, No. 1, Chang-De Street, Taipei 10048, Taiwan.

E-mail address: [leejj@ntuh.gov.tw](mailto:leejj@ntuh.gov.tw) (J.-J. Lee).

clinicians to improve their practice and optimize patient outcomes by providing evidence-based strategies.

© 2025 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

With increasing life expectancy, the global elderly population is also increasing, leading to an increase in osteoporosis cases.<sup>1</sup> According to data from Taiwan's National Health Insurance system, the prevalence of osteoporosis among individuals aged 50 years and older has exhibited a substantial increase, increasing from 17.4 % in 2001 to 25.0 % in 2011.<sup>2,3</sup> However, the actual prevalence may have been underestimated because osteoporosis often remains asymptomatic and undiagnosed. This finding emphasizes the critical need for enhanced awareness, early detection, and proactive intervention strategies in this demographic group. Patients with osteoporosis have an elevated risk of severe fractures owing to decreased bone mineral density and compromised structural integrity.<sup>4</sup> In Taiwan, elderly patients with osteoporosis-related hip fractures exhibit significantly higher one-year mortality rates (11.2 % in women and 18.0 % in men) than their counterparts without fractures (2.8 % and 3.6 %, respectively).<sup>5</sup> Prolonged post-fracture immobilization can result in significant complications including compromised circulatory function and increased susceptibility to infections, which are major contributors to fracture-related mortality.<sup>6</sup> Early therapeutic intervention for osteoporosis is crucial to mitigate the risk of severe fractures and related mortality.

The primary treatment for osteoporosis involves medication,<sup>7,8</sup> such as anti-resorptive agents that inhibit osteoclast activity and anabolic agents that promote bone formation (Fig. 1A). In 2003, concerns were raised about the use of bisphosphonates (BPs), a class of anti-resorptive drugs such as zoledronate, pamidronate, and alendronate, owing to potential side effects that could lead to osteonecrosis of the jaw (Fig. 1B).<sup>9</sup> The American Association of Oral and Maxillofacial Surgeons (AAOMS) classified these conditions as medication-related osteonecrosis of the jaw (MRONJ) in 2014 and modified the definition in 2022 as understanding increases.<sup>10,11</sup> A staging system for MRONJ has also been introduced and modified using the AAOMS. The typical symptoms of MRONJ include pain, gingival swelling, paresthesia of the lower lip, suppuration, tooth loosening, and necrotic bone exposure, which are signs of infection. Radiographic images may reveal osteolysis, osteosclerosis, sequestral formations, and pathological fractures (Fig. 2).

Approximately half of the MRONJ cases are associated with invasive dental procedures, such as dental extraction and implant placement, performed during anti-resorptive therapy (ART),<sup>12,13</sup> which is a finding that has caused considerable concern and apprehension among dentists. Dental practitioners may be reluctant to provide care for


patients receiving ART owing to the paucity of standardized clinical protocols, even for simple dental procedures, resulting in potentially unnecessary specialist referrals. Such clinical hesitancy may compromise the timely intervention and optimal management of oral health conditions in this patient population. Conversely, owing to an insufficient understanding of MRONJ, some dentists may perform invasive dental surgeries, such as extractions and implant placements, without implementing adequate preventive strategies during ART, potentially leading to unnecessary MRONJ cases. This paradox of excessive precaution and knowledge-based neglect reflects the current challenges faced by dental practitioners in managing patients with osteoporosis receiving ART. In response to this knowledge gap, this review sought to provide evidence-based guidance for dental practitioners to optimize their clinical management protocols.

## Risk assessment and prevalence of medication-related osteonecrosis of the jaw in patients with osteoporosis

The prevalence of MRONJ among patients with osteoporosis receiving ART ranged from 0.02 % to 0.3 % across all pharmacological agents, with a potential tenfold increase in risk following dentoalveolar surgical interventions (Fig. 3).<sup>11</sup> Current evidence indicates that patients with osteoporosis receiving ART have a low incidence of MRONJ, with risk stratification varying significantly among the different dental treatments. Fig. 3 illustrates the spectrum of invasive dental procedures that warrant particular attention in clinical risk assessments by dental practitioners. This article discusses five major risk factors and minor factors associated with dental practice for MRONJ.

### First factor: invasive dentoalveolar procedures

Dentoalveolar surgical procedures, specifically tooth extraction and implant placement, are recognized as primary risk factors for MRONJ development owing to their associated alveolar trauma. Epidemiological studies have demonstrated that tooth extraction represents a significant precipitating event in MRONJ cases, with reported data indicating an approximately nine-fold increase in the incidence of MRONJ.<sup>14</sup> A nationwide retrospective cohort analysis utilizing Taiwan's National Health Insurance Research Database aligned with these findings, demonstrating that patients with osteoporosis receiving alendronate therapy who underwent tooth extraction experienced a 9.6-fold higher risk of MRONJ than their non-extraction



**Figure 1** Medications for osteoporosis and their effects on bone remodeling. (A) The diagram outlines the different classes of medications used to manage osteoporosis. Anabolic agents like parathyroid hormone (PTH) and PTH-related protein (PTHrP) stimulate osteoblast (OB) activity to promote bone formation. In contrast, antiresorptive agents such as bisphosphonates (BPs), receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors, and selective estrogen receptor modulators (SERMs) inhibit osteoclast (OC) activity to reduce bone resorption. Dual-effect agents can both decrease OC-mediated resorption and enhance OB-driven bone formation. (B) Effects on bone remodeling. Normal bone remodeling involves a balance between OC and OB activity. By inhibiting OC activity and reducing bone resorption, antiresorptive agents can lead to decreased bone turnover. This alteration in bone remodeling may potentially impair the healing of extraction wounds and lead to medication-related osteonecrosis of jaws.

counterparts.<sup>15</sup> Additionally, 52–61 % of MRONJ-affected sites have previously undergone tooth extraction.<sup>16–21</sup> In the following paragraphs, the most common invasive dentoalveolar procedures performed in dental clinics are discussed.

#### Dental extractions

For patients undergoing ART, minimizing elective dentoalveolar surgery is recommended where clinically feasible. However, dentoalveolar surgery should not be considered an absolute contraindication. In the presence of active dental infections, prompt therapeutic intervention is essential to prevent the progression to severe infections and potential MRONJ development. When clinical manifestations of infection are present, and tooth preservation through conservative measures is not feasible, surgical extraction remains the recommended therapeutic approach. The following precautions should be taken when extracting teeth:

1. Administer prophylactic antibiotics 1 h preoperatively.
2. Use minimal flap design with periosteal preservation to maintain blood supply.
3. Minimize bone removal with copious saline irrigation.
4. Limit extractions to fewer than three teeth per quadrant.
5. Achieve primary soft tissue closure to minimize bone exposure.
6. Avoid bone graft materials to prevent foreign body reactions.
7. Prescribe postoperative antibiotics and chlorhexidine mouth rinse.

#### Dental implantations

According to the MRONJ position paper published by AAOMS in 2014, the risk of developing MRONJ following dental implant procedures is similar to that associated with tooth extraction.<sup>10</sup> While the current evidence suggests that ART

|                             | Stage 0                                                                                                                                                                                                                                                                                                                                                                                                                               | Stage 1                                                                               | Stage 2                                                                                 | Stage 3                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Exposed bone</b>         | <ul style="list-style-type: none"> <li>No exposed bone</li> </ul>                                                                                                                                                                                                                                                                                                                                                                     | <ul style="list-style-type: none"> <li>Exposed bone</li> <li>Necrotic bone</li> </ul> | <ul style="list-style-type: none"> <li>Exposed bone</li> <li>Necrotic bone</li> </ul>   | <ul style="list-style-type: none"> <li>Exposed bone</li> <li>Necrotic bone</li> </ul>                                                                                                                                                                                                                                                                                                                |
| <b>Patient symptom</b>      | <ul style="list-style-type: none"> <li>Non-specific</li> <li>Odontalgia (not odontogenic cause)</li> <li>Dull pain</li> </ul>                                                                                                                                                                                                                                                                                                         | <ul style="list-style-type: none"> <li>No symptom</li> </ul>                          | <ul style="list-style-type: none"> <li>Symptomatic</li> <li>Pain</li> </ul>             | <ul style="list-style-type: none"> <li>Symptomatic</li> <li>Pain</li> </ul>                                                                                                                                                                                                                                                                                                                          |
| <b>Infection sign</b>       | <ul style="list-style-type: none"> <li>No infection</li> </ul>                                                                                                                                                                                                                                                                                                                                                                        | <ul style="list-style-type: none"> <li>No infection</li> </ul>                        | <ul style="list-style-type: none"> <li>With infection</li> <li>Erythema, pus</li> </ul> | <ul style="list-style-type: none"> <li>With infection sign</li> <li>≥ 1 of following               <ul style="list-style-type: none"> <li>✓ Extending beyond alveolar region</li> <li>✓ Pathologic fracture</li> <li>✓ Extraoral fistula</li> <li>✓ Oroantral or oronasal communication</li> <li>✓ Osteolysis extending to the inferior border of the mandible or sinus floor</li> </ul> </li> </ul> |
| <b>Radiographic finding</b> | Localized to the alveolar bone region <ul style="list-style-type: none"> <li>Alveolar bone loss/resorption (not chronic periodontal disease)</li> <li>Changes to trabecular pattern sclerotic bone and no new bone in extraction sockets</li> <li>Osteosclerosis involving the alveolar bone and/or the surrounding basilar bone</li> <li>Thickening of the lamina dura/decreased size of periodontal ligament (PDL) space</li> </ul> |                                                                                       |                                                                                         | Beyond alveolar bone                                                                                                                                                                                                                                                                                                                                                                                 |

**Figure 2** Stage descriptions for medication-related osteonecrosis of the jaw based on key clinical features, including exposed bone, patient symptoms, infection signs, and radiographic findings.

| Bisphosphonates (BPs)                                                                                                                                                                                                                                                                                                                      |                        |                        | Selective estrogen receptor modulators (SERMs) | Receptor activator of nuclear factor-κB ligand (RANKL) inhibitor | Sclerostin inhibitor |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|------------------------|------------------------------------------------|------------------------------------------------------------------|----------------------|
| Oral                                                                                                                                                                                                                                                                                                                                       | Intravenous            |                        | Oral                                           | Subcutaneous                                                     | Subcutaneous         |
| Alendronate (Fosamax®)                                                                                                                                                                                                                                                                                                                     | Zoledronate (Aclasta®) | Ibandronate (Bonviva®) | Raloxifene (Evista®)                           | Denosumab (Prolia™)                                              | Romosumab (Evenity™) |
| < 0.05 %<br>0.21 % (>4Y)                                                                                                                                                                                                                                                                                                                   | < 0.02 %               | Lower than other BPs   | Extremely low                                  | 0.04% (3Y)<br>0.06% (5Y)<br>0.3 % (10Y)                          | 0.03 - 0.05 %        |
| <b>With dentoalveolar surgery, including:</b> <ul style="list-style-type: none"> <li>Extraction or odontectomy</li> <li>Dental implantation</li> <li>Alveoloplasty</li> <li>Bone biopsy/excision</li> <li>Periodontal flap operation</li> <li>Crown lengthening procedure</li> <li>Periapical surgery</li> <li>Cyst enucleation</li> </ul> |                        |                        |                                                |                                                                  |                      |
| 0 - 0.15 %                                                                                                                                                                                                                                                                                                                                 | 0 - 0.15 %             | ?                      | ?                                              | 1 %<br>(0.5-1%)                                                  | ?                    |

**Figure 3** Prevalence of medication-related osteonecrosis of jaws (MRONJ) associated with different antiresorptive agents. It has been reported the prevalence of MRONJ increases when patients underwent dentoalveolar surgeries, such as tooth extractions or apical surgeries.

does not significantly affect dental implant success rates, dental practitioners should remain aware that implant placement procedures carry an inherent risk of MRONJ, which may compromise implant survival.<sup>22–24</sup> Thus, comprehensive patient counseling regarding potential risks is essential before implant therapy. The following protocol is recommended for implant placement:

1. Administer prophylactic antibiotics 1 h preoperatively.
2. Apply aseptic and minimally invasive techniques (flapless or mini-flap approaches).
3. Maintain copious saline irrigation during osteotomy preparation.
4. Avoid bone grafts or regenerative materials.
5. Select a two-stage submerged implant protocol over one-stage surgery.
6. Ensure primary soft tissue closure.
7. Prescribe postoperative antibiotics and chlorhexidine mouth rinse.
8. Implement regular monitoring at 3–6 month intervals.

Successfully implanted dental implants carry the risk of developing MRONJ, which can be categorized into early- and late-onset osteonecrosis of the jaw.<sup>25</sup> Early-onset MRONJ, also known as early implant surgery-triggered osteonecrosis, is often associated with the surgical procedure itself and typically occurs 2–10 months after implant placement, leading to implant failure. In contrast, late-onset MRONJ referred to as late implant presence-triggered necrosis, is caused by the long-term use of the implant due to improper force distribution or peri-implantitis.<sup>26</sup> Moreover, the soft tissue toxicity associated with BPs increases the incidence and treatment complexity of peri-implantitis.<sup>27</sup> Therefore, patients receiving ART require more rigorous post-implantation monitoring than the standard protocols, to minimize inflammatory complications and subsequent MRONJ development.

## Second factor: concomitant oral infection

The second most significant risk factor for MRONJ was concomitant oral infection. Notably, 50 % of the MRONJ cases were not associated with the previously discussed invasive dentoalveolar procedures. However, they rather originated from inflammatory conditions such as periodontitis, apical periodontitis, and peri-implantitis.<sup>28,29</sup> The key strategies for MRONJ prevention include maintaining oral health and carefully assessing surgical requirements during ART. Regular dental checkups and early treatment of oral problems reduce the need for tooth extraction during ART.<sup>30</sup> Furthermore, regular dental examinations (every 6 months) and maintenance of optimal oral hygiene reduce the incidence of MRONJ from 4.6 % to 0.8 %, representing an 83 % reduction.<sup>31</sup>

## Third factor: types of medication

The third major risk factor for MRONJ is the pharmacokinetic differences among drugs, which requires consideration of the potency of anti-resorptive agents and their bone-binding ability. A higher drug potency correlates with

enhanced therapeutic efficacy against osteoporosis; however, it corresponds to an increased risk of developing MRONJ.<sup>32,33</sup> The skeletal distribution of drugs is determined by their binding affinities. High-affinity agents exhibit longer half-lives, increased MRONJ incidence, and prolonged healing periods following the onset of MRONJ.<sup>34,35</sup> The subsequent discussion addresses two major categories of anti-resorptive agents: BPs and denosumab (DMB).

### Bisphosphonates


Upon entering the body, BPs establish strong bonds with the bone matrix, which enables their release during osteoclastic bone resorption. This results in BPs entering osteoclasts and interfering with their metabolic functions, ultimately causing osteoclast dysfunction or apoptosis.<sup>36,37</sup> Furthermore, BPs demonstrate remarkable skeletal stability and resistance to metabolic degradation.<sup>38</sup> For example, alendronate has a half-life exceeding 10 years, suggesting that temporary drug discontinuation has a minimal effect on systemic drug concentration. Regarding bone binding affinity, zoledronate was ranked as the strongest, followed by alendronate and ibandronate.<sup>39</sup> Regarding potency, zoledronate exhibited the highest efficacy and was approximately ten times more potent than ibandronate and one hundred times more potent than alendronate.<sup>40</sup>

### Denosumab

The monoclonal antibody DMB, a receptor activator of nuclear factor kappa-B ligand (RANKL), primarily acts on the bloodstream rather than on the bone. Under normal physiological conditions, RANKL binds to its receptors on pre-osteoclasts and activates them into mature osteoclasts.<sup>41</sup> DMB functions by binding to RANKL, rendering it ineffective, and thereby reducing the production of mature osteoclasts.<sup>42</sup> Notably, the potency of DMB is comparable to that of zoledronate, making it a considerably potent drug.<sup>43,44</sup> Since DMB does not bind to bone and has a half-life in the blood of 25–30 days,<sup>45</sup> the effects of DMB on bone turnover are fully reversible after discontinuation.<sup>46</sup> Consequently, alterations in bone remodeling and wound healing were restored if DMB was discontinued for 2–3 months.<sup>47,48</sup>

## Fourth factor: duration of medication

The fourth major risk factor for MRONJ is the duration of drug use. According to the U.S. Adverse Event Reporting System of the Food and Drug Administration, the median interval between the initiation of drug therapy and the onset of MRONJ ranges from 5 months to approximately 2 years (Fig. 4).<sup>49</sup> Therefore, the prevalence of MRONJ in patients with osteoporosis undergoing ART is low, with no statistically significant difference observed between BPs and DMB.<sup>11</sup> Nevertheless, the prolonged use of BPs, characterized by their long half-life, results in a cumulative dose effect, consequently leading to a significant increase in MRONJ risk over time.<sup>50</sup> In contrast, DMB exhibited a more consistent MRONJ risk profile despite long-term administration owing to its shorter half-life and the absence of the pronounced accumulation effect observed with BPs.<sup>51</sup> The risk of MRONJ significantly increases with



| The onset time for medication-related osteonecrosis of the jaw |                 |               |              |
|----------------------------------------------------------------|-----------------|---------------|--------------|
| Medication                                                     | Brand name      | Median (days) | Q1, Q3       |
| <b>Medications for osteoporosis</b>                            |                 |               |              |
| <b>Zoledronate</b>                                             | <b>Aclasta®</b> | 730           | 368, 1268    |
| <b>Denosumab</b>                                               | <b>Prolia™</b>  | 489.5         | 236.3, 909.8 |
| <b>Ibandronate</b>                                             | <b>Bonviva®</b> | 722.5         | 314, 1055    |
| <b>Risedronate</b>                                             | <b>Reosteo®</b> | 761           | 368, 1720    |
| <b>Romosozumab</b>                                             | <b>Evenity™</b> | 153           | 50, 346      |
| <b>Medications for cancer</b>                                  |                 |               |              |
| <b>Zoledronate</b>                                             | <b>Zometa®</b>  | 680.5         | 255.3, 1283  |
| <b>Denosumab</b>                                               | <b>Xgeva®</b>   | 488           | 245, 851     |
| <b>Pamidronate</b>                                             | <b>Aredia®</b>  | 696.5         | 347, 1087    |

Figure 4 Median interval between the initiation of drug therapy and the onset of MRONJ.

extended use, such as when alendronate is used for >4 years or DMB is used for >10 years, with the risk increasing to 0.21 %<sup>52</sup> and 0.3 %, <sup>53</sup> respectively (Fig. 3). Moreover, the risk of MRONJ persists even after the discontinuation of osteoporosis treatment owing to the prolonged residual effects of BPs in the bone.<sup>54</sup>

### Fifth factor: drug discontinuation

The fifth major risk factor of MRONJ is the lack of appropriate drug discontinuation before invasive dentoalveolar procedures. However, the necessity of preoperative drug discontinuation remains controversial.<sup>10,11,33,55</sup> However, based on pharmacokinetic reasoning, temporarily discontinuing the use of anti-resorptive agents before

dentoalveolar surgery to reduce their concentration in the body should reduce the occurrence of MRONJ.<sup>56,57</sup> Drug discontinuation has emerged as the primary modifiable factor within the dentist's control, highlighting the critical role of interdisciplinary collaboration in patient care. The recommended discontinuation intervals for individual medications before dentoalveolar surgery are shown in Fig. 5. Supporting evidence for these recommendations is discussed below.

#### Bisphosphonates: alendronate

In 2022, the AAOMS recommended that patients with 4 or more years of alendronate exposure or those who were exposed to alendronate for less than 4 years and in combination with steroids or anti-angiogenic medications should discontinue alendronate 2 months before tooth

| Treatment of osteoporosis                                             |                                          | Discontinuation of medication before dental procedure |                                                                                                                                                                                     |                                  |                                                                                                     |
|-----------------------------------------------------------------------|------------------------------------------|-------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------|
| Medication<br>(Brand name)                                            | Route/<br>Frequency                      | Non-invasive                                          | Invasive-<br>tooth extraction                                                                                                                                                       | Invasive-<br>dental implantation | Resume timing                                                                                       |
| Anabolic agents (Promoting bone formation)                            |                                          |                                                       |                                                                                                                                                                                     |                                  |                                                                                                     |
| Teriparatide<br>(Forteo®)                                             | Subcutaneous,<br>daily<br>(For 1.5Y)     | Continued                                             | Continued                                                                                                                                                                           | Continued                        | -                                                                                                   |
| Antiresorptive agents (Reducing bone resorption)                      |                                          |                                                       |                                                                                                                                                                                     |                                  |                                                                                                     |
| Bisphosphonates, BPs                                                  |                                          |                                                       |                                                                                                                                                                                     |                                  |                                                                                                     |
| Alendronate<br>(Fosamax®)                                             | Oral,<br>daily                           | Continued                                             | <ul style="list-style-type: none"><li>• &lt;4Y: continued</li><li>• &lt;4Y + steroid or antiangiogenic medications:<br/>discontinued 2M</li><li>• &gt;4Y: discontinued 2M</li></ul> |                                  | <ul style="list-style-type: none"><li>• Post-extraction 1M</li><li>• Post-implantation 3M</li></ul> |
| Ibandronate<br>(Bonviva®)                                             | Intravenous,<br>Q3M                      |                                                       | <ul style="list-style-type: none"><li>• Continued</li><li>• 3M after last dose</li></ul>                                                                                            |                                  |                                                                                                     |
| Zoledronate<br>(Aclasta®)                                             | Intravenous,<br>annual                   |                                                       | <ul style="list-style-type: none"><li>• 3M after last dose</li></ul>                                                                                                                |                                  |                                                                                                     |
| Receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor |                                          |                                                       |                                                                                                                                                                                     |                                  |                                                                                                     |
| Denosumab<br>(Prolia™)                                                | Subcutaneous,<br>Q6M                     | Continued                                             | <ul style="list-style-type: none"><li>• 3M after last dose</li></ul>                                                                                                                |                                  | <ul style="list-style-type: none"><li>• Post-extraction 1M</li><li>• Post-implantation 3M</li></ul> |
| Selective estrogen receptor modulators (SERMs)                        |                                          |                                                       |                                                                                                                                                                                     |                                  |                                                                                                     |
| Raloxifene<br>(Evista®)                                               | Oral,<br>daily                           | Continued                                             | Continued                                                                                                                                                                           | Continued                        | -                                                                                                   |
| Dual-effect agents (anabolic + antiresorptive)                        |                                          |                                                       |                                                                                                                                                                                     |                                  |                                                                                                     |
| Romosumab<br>(Evenity™)                                               | Subcutaneous,<br>monthly<br>(For 1 year) | Continued                                             | <ul style="list-style-type: none"><li>• Continued</li><li>• After 3 doses</li></ul>                                                                                                 |                                  | As scheduled                                                                                        |
| Sequential treatment (2 or more medication in succession)             |                                          |                                                       |                                                                                                                                                                                     |                                  |                                                                                                     |
| Any                                                                   | -                                        | Continued                                             | Follow the current medication                                                                                                                                                       |                                  |                                                                                                     |

**Figure 5** Recommended discontinuation intervals for individual medications before dentoalveolar surgery. The timing for resuming medication after dentoalveolar surgery is also listed in the figure.

extraction.<sup>11</sup> This recommendation can be attributed to the fact that a fraction of alendronate remains unbound in the bloodstream with a half-life of 28 days,<sup>58</sup> potentially impeding epithelial healing owing to its soft tissue toxicity, thereby increasing the risk of exposing the underlying alveolar socket.<sup>59</sup> Therefore, the temporary discontinuation of alendronate may reduce its systemic concentration and potentially mitigate its adverse effects on extraction wound healing.

#### Bisphosphonates: zoledronate

Zoledronate, a highly potent nitrogen-containing BP, is associated with MRONJ in patients with osteoporosis. Pre-clinical studies have demonstrated that zoledronate inhibits epithelial cell migration and bone healing following tooth extraction.<sup>60,61</sup> Following infusion, the bone resorption marker C-telopeptide (CTX) reached maximum suppression in 9–11 days and maintained this suppression for approximately 3 months before gradual recovery, whereas the bone formation marker P1NP showed maximum suppression at 3 months post-infusion.<sup>62</sup> Based on these pharmacological principles, dentoalveolar surgery should be considered at least 3 months after previous zoledronate administration. Our recent clinical investigation demonstrated that a 3-month drug interruption with zoledronate significantly reduced MRONJ risk, supporting this strategy.<sup>63</sup>

#### Bisphosphonates: ibandronate

Ibandronate, a high-potency BP characterized by its relatively low binding affinity for bone minerals, has a lower risk of inducing MRONJ than other BPs.<sup>64</sup> While the precise incidence has not been established, the literature currently contains only isolated case reports of ibandronate-associated MRONJ.<sup>65–67</sup> Moreover, no reported guidelines were observed for the discontinuation of ibandronate before dentoalveolar surgery. Given the pharmacokinetic profile of ibandronate, discontinuation of the medication may not be necessary before dentoalveolar procedures. However, if a drug interruption is deemed appropriate, we propose that dentoalveolar surgeries be scheduled approximately 3 months after the last ibandronate administration, aligning with the general recommendations for most anti-resorptive agents.

#### Receptor activator of nuclear factor kappa-B ligand inhibitor: denosumab

In 2022, the AAOMS also recommended that dentoalveolar surgeries be scheduled—3–4 months after the last dose of DMB, when the level of osteoclast inhibition is waning.<sup>11</sup> Emphasizing that while DMB has a relatively short half-life, and its discontinuation can effectively reduce its systemic concentration, prolonged or arbitrary cessation of therapy may precipitate a serious adverse event known as

rebound-associated multiple vertebral fractures.<sup>68,69</sup> Therefore, not delaying the subsequent dose by more than 1 month to maintain optimal therapeutic efficacy is recommended.<sup>70</sup> This highlights the importance of carefully managing DMB discontinuation to minimize potential risks to patients.

#### **Selective estrogen receptor modulators: raloxifene**

Raloxifene, a selective estrogen receptor modulator,<sup>71</sup> has a different mechanism of action from other anti-resorptive medications. It mimics the effects of estrogen and exerts limited inhibition of osteoclast activity, helping to maintain bone density at levels comparable to those observed in premenopausal women.<sup>72–74</sup> To date, reported MRONJ cases associated with raloxifene treatment are extremely rare.<sup>75,76</sup> Consequently, the current recommendations suggest that discontinuation of raloxifene before invasive dental procedures is unnecessary.

#### **Anabolic agent: teriparatide**

Teriparatide, a recombinant human parathyroid hormone, is prescribed as an anabolic agent for increasing the rate of bone formation.<sup>77</sup> Emerging evidence suggests that teriparatide may enhance post-extraction alveolar bone healing and promote the osseointegration of dental implants.<sup>78,79</sup> Therefore, discontinuing the medication preoperatively is not necessary.

#### **Dual-effect agent: romosozumab**

Romosozumab, with the dual effect of promoting bone formation and inhibiting bone resorption,<sup>80</sup> lacks specific guidelines for its discontinuation before dentoalveolar surgery owing to its recent introduction. Regarding pharmacological effects, the inhibitory effect of romosozumab on osteoclasts is relatively milder than that of DMB; however, both have comparable effects in promoting bone mineral density.<sup>81</sup> Analysis of bone resorption markers indicated a significant decrease in CTX levels within the first week following romosozumab injection, which gradually returned to baseline by the third month. These findings suggest that after three doses of romosozumab, the inhibitory effects on osteoclasts markedly decreased, with their activity approaching pretreatment levels.<sup>82,83</sup> Therefore, romosozumab discontinuation before dentoalveolar surgery was not deemed necessary. Alternatively, scheduling dentoalveolar procedures after the third monthly romosozumab injection may be considered a relatively safe approach.

#### **Sequential use of two or more medications**

An increasing number of patients with osteoporosis are receiving sequential therapy, which involves the administration of two or more medications in succession. For instance, current strategies initially employ anabolic agents followed by potent anti-resorptive agents. This combination effectively reduced the fracture risk rapidly and yielded substantial gains in bone mineral density.<sup>84–86</sup> The prolonged skeletal retention of BPs necessitates careful consideration when transitioning to DMB owing to potential pharmacological interactions, which is associated with a possible overlapping effect, resulting in dual osteoclastic inhibition. This may theoretically increase the risk of

MRONJ. Furthermore, extended cumulative anti-resorptive exposure in sequential BP-to-DMB therapy could increase the risk of MRONJ during invasive dental procedures.<sup>87</sup> In principle, a drug discontinuation plan should be tailored to a patient's current medication regimen.

#### **Timing for resuming anti-resorptive therapy after dentoalveolar surgery**

For patients undergoing dentoalveolar surgery who have temporarily discontinued ART, an important consideration is the timing of ART resumption following the completion of these procedures. We recommend that for BPs and DMB, ART be resumed 1-month post-extraction and 3 months post-dental implantation to allow complete soft tissue healing and osseointegration.<sup>88,89</sup> A subsequent dose of romosozumab was administered according to a regular monthly schedule (Fig. 5).

#### **Other risk factors of medication-related osteonecrosis of the jaw**

While numerous risk factors for MRONJ development have been identified, including systemic (such as diabetes, rheumatic arthritis, and cancer), demographic (such as age), and genetic variables (such as PPAR gamma and CYP2C8),<sup>11</sup> the following discussion primarily focuses on local factors associated with dental practices.

#### **Tooth extraction site**

Extraction of the posterior mandibular teeth poses a higher risk of MRONJ development than other extraction sites.<sup>63</sup> Several factors may have contributed to this increased risk. First, blood circulation in the mandible is less abundant than that in the maxilla, potentially compromising healing.<sup>90</sup> Secondly, the complex root structure of the lower posterior teeth often necessitates more invasive extraction procedures, making it challenging to perform atraumatic extractions.<sup>91</sup> Lastly, achieving primary wound closure in this region is often challenging and frequently requires additional alveolectomies and flap advancement procedures. Cases with primary closure after extraction have been reported to be less likely to develop MRONJ.<sup>92</sup>

#### **Ill-fitted removable denture**

Ill-fitted removable dentures may exert excessive pressure on the alveolar ridge, potentially leading to mucosal trauma and subsequent alveolar bone exposure,<sup>93,94</sup> thus elevating the risk of MRONJ.<sup>17,20</sup> Notably, MRONJ can develop in areas with dental problems and edentulous regions. Therefore, patients should undergo regular evaluations and denture adjustments to minimize the incidence of spontaneous MRONJ. This proactive approach to denture maintenance is crucial to mitigate the risk of MRONJ in patients undergoing ART.

#### **Exostosis**

Exostosis, a manifestation of bone overgrowth, is characterized by prominent protrusions that are typically observed at the midline of the hard palate and lingual aspect of the mandible.<sup>95</sup> The mucosal tissue overlying these exostoses is often attenuated, rendering it

susceptible to ulceration and bone exposure when subjected to mechanical stress during mastication, thereby increasing the risk of MRONJ.<sup>96,97</sup> Alveoloplasty, a dentoalveolar surgery, is contraindicated in patients undergoing ART; however, patient education focusing on careful mastication and avoidance of hard or sharp food items is essential to prevent mucosal trauma and subsequent complications. Furthermore, dental practitioners should minimize mechanical friction when obtaining impressions from prosthetic devices.

### Differentiation between pre-existing medication-related osteonecrosis of the jaw and periodontitis

MRONJ without bone exposure may initially present solely as tooth mobility, potentially leading to misdiagnosis of periodontitis. This misdiagnosis could result in tooth extraction, which may subsequently be erroneously identified as extraction-induced MRONJ. Clinically, both conditions share features, such as deep periodontal pockets, tooth mobility, and localized abscesses.<sup>98</sup> However, distinctions can be observed in tooth vitality; teeth affected by periodontitis typically exhibit normal pulp responses, whereas those affected by MRONJ may demonstrate pulp necrosis.<sup>99</sup> A crucial differentiating factor lies in the pocket location: in periodontitis, the pocket forms between the alveolar bone and the root surface, whereas in MRONJ, it develops between the gingiva and the alveolar bone, reflecting the underlying osseous etiology.<sup>11</sup> Radiographically, periodontitis is characterized by alveolar bone resorption and a discontinuous lamina dura in the crestal bone. In contrast, MRONJ-affected teeth do not show bone resorption and may exhibit thickening of the lamina dura, a feature specifically observed in patients using BPs.<sup>100,101</sup> Understanding these features will enable dental practitioners to effectively identify preexisting MRONJ, facilitating more accurate risk assessment and informed clinical decision-making.

### Conclusion

Clinical guidelines provide a general safety consensus; however, they cannot guarantee the prevention of MRONJ in all cases. While extended preoperative drug interruption may yield safer outcomes, it significantly disrupts osteoporosis treatment. Notably, current recommendations for drug discontinuation before dentoalveolar surgery are not based on comprehensive prospective clinical trials but on retrospective cohort studies and pharmacological inferences. Consequently, adherence to these guidelines does not ensure complete prevention of MRONJ. However, it serves to minimize its risk. Various uncontrollable factors persist, such as ART duration, concurrent therapy, anatomical site of intervention, and comorbidities, all of which may contribute to an increased risk of MRONJ. Dental practitioners should always inform patients of the risk of MRONJ before invasive dental procedures and provide alternative treatment options when feasible.

In conclusion, this review presents the first specific guidelines for preoperative drug discontinuation tailored to individual anti-resorptive agents in patients with

osteoporosis undergoing dentoalveolar surgery. By identifying the significant risk factors for personalized assessment and offering applicable surgical precautions, this article aids dental practitioners in optimizing patient outcomes. We recommend temporarily discontinuing certain anti-resorptive agents before dentoalveolar surgery to minimize the risk of MRONJ.

### Declaration of competing interest

The authors declare that they have no competing financial interests or personal relationships that may have influenced the work reported in this study.

### Acknowledgments

This work was partially supported by the National Science and Technology Council, Taiwan, under grant [109-2314-B-002-036-MY3] to Jang-Jaer Lee, and grant [111-2314-B-002-063] to Ling-Ying Wei.

### References

- Salari N, Ghasemi H, Mohammadi L, et al. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. *J Orthop Surg Res* 2021;16: 609.
- Lin YC, Pan WH. Bone mineral density in adults in taiwan: results of the nutrition and health survey in Taiwan 2005-2008 (NAHSIT 2005-2008). *Asia Pac J Clin Nutr* 2011;20:283–91.
- Chen FP, Huang TS, Fu TS, Sun CC, Chao AS, Tsai TL. Secular trends in incidence of osteoporosis in Taiwan: a nationwide population-based study. *Biomed J* 2018;41:314–20.
- Sözen T, Özişik L, Başaran N. An overview and management of osteoporosis. *Eur J Rheumatol* 2017;4:46–56.
- Tai TW, Huang CF, Huang HK, et al. Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: 2022 update. *J Formos Med Assoc* 2023;122(Suppl 1): S4–13.
- Panula J, Pihlajamäki H, Mattila VM, et al. Mortality and cause of death in hip fracture patients aged 65 or older: a population-based study. *BMC Musculoskelet Disord* 2011;12: 105.
- Haas AV, LeBoff MS. Osteoanabolic agents for osteoporosis. *J Endocr Soc* 2018;2:922–32.
- Li H, Xiao Z, Quarles LD, Li W. Osteoporosis: mechanism, molecular target and current status on drug development. *Curr Med Chem* 2021;28:1489–507.
- Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. *J Oral Maxillofac Surg* 2003;61:1115–7.
- Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. *J Oral Maxillofac Surg* 2014;72:1938–56.
- Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaws-2022 Update. *J Oral Maxillofac Surg* 2022;80: 920–43.
- Aljohani S, Fliefel R, Ihbe J, Kühnisch J, Ehrenfeld M, Otto S. What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw

- (MRONJ) in osteoporosis patients: a systematic review. *J Cranio-Maxillo-Fac Surg* 2017;45:1493–502.
13. Hallmer F, Andersson G, Götrick B, Warfvinge G, Anderud J, Bjørnland T. Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw—a 4-year prospective study. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2018;126:477–85.
  14. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. *J Oral Maxillofac Surg* 2007;65:415–23.
  15. Chiu WY, Yang WS, Chien JY, Lee JJ, Tsai KS. The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects. *PLoS One* 2018;13:e0196419.
  16. Fehm T, Beck V, Banys M, et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): incidence and risk factors in patients with breast cancer and gynecological malignancies. *Gynecol Oncol* 2009;112:605–9.
  17. Kyrgidis A, Vahtsevanos K, Koloutsos G, et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. *J Clin Oncol* 2008;26:4634–8.
  18. Utreja A, Almas K, Javed F. Dental extraction as a risk factor for bisphosphonate related osteonecrosis of the jaw in cancer patients: an update. *Odonto-Stomatol Trop* 2013;36:38–46.
  19. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. *Ann Oncol* 2012;23:1341–7.
  20. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. *J Clin Oncol* 2009;27:5356–62.
  21. Sanchis JM, Bagán JV, Murillo J, Díaz JM, Asensio L. Risk of developing BRONJ among patients exposed to intravenous bisphosphonates following tooth extraction. *Quintessence Int* 2014;45:769–77.
  22. Guazzo R, Sbricoli L, Ricci S, Bressan E, Piattelli A, Iaculli F. Medication-related osteonecrosis of the jaw and dental implants failures: a systematic review. *J Oral Implantol* 2017;43:51–7.
  23. Granate-Marques A, Polis-Yanes C, Seminario-Amez M, Jané-Salas E, López-López J. Medication-related osteonecrosis of the jaw associated with implant and regenerative treatments: systematic review. *Med Oral Patol Oral Cir Bucal* 2019;24:e195–203.
  24. Papadakis I, Spanou A, Kalyvas D. Success rate and safety of dental implantology in patients treated with antiresorptive medication: a systematic review. *J Oral Implantol* 2021;47:169–80.
  25. Giovannacci I, Meleti M, Manfredi M, et al. Medication-related osteonecrosis of the jaw around dental implants: implant surgery-triggered or implant presence-triggered osteonecrosis? *J Craniofac Surg* 2016;27:697–701.
  26. Holzinger D, Seemann R, Matoni N, Ewers R, Milesi W, Wutzl A. Effect of dental implants on bisphosphonate-related osteonecrosis of the jaws. *J Oral Maxillofac Surg* 2014;72:1937.e1–8.
  27. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? *Bone* 2007;41:318–20.
  28. Yamazaki T, Yamori M, Ishizaki T, et al. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. *Int J Oral Maxillofac Surg* 2012;41:1397–403.
  29. McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: a systematic review. *Oral Dis* 2018;24:527–36.
  30. Vandone AM, Donadio M, Mozzati M, et al. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. *Ann Oncol* 2012;23:193–200.
  31. Poxleitner P, Engelhardt M, Schmelzeisen R, Voss P. The prevention of medication-related osteonecrosis of the jaw. *Dtsch Arztebl Int* 2017;114:63–9.
  32. Lee SH, Choi SY, Bae MS, Kwon TG. Characteristics of patients with osteonecrosis of the jaw with oral versus intravenous bisphosphonate treatment. *Maxillofac Plast Reconstr Surg* 2021;43:24.
  33. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. *J Bone Miner Res* 2015;30:3–23.
  34. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. *Mayo Clin Proc* 2008;83:1032–45.
  35. Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. *Cancer Treat Rev* 2018;69:177–87.
  36. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. *Cancer* 2000;88:2961–78.
  37. Rogers MJ. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. *Calcif Tissue Int* 2004;75:451–61.
  38. Russell RG. Bisphosphonates: the first 40 years. *Bone* 2011;49:2–19.
  39. Inderjeeth CA, Glendenning P, Ratnagopal S, Inderjeeth DC, Ondhia C. Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis. *Int J Womens Health* 2015;7:7–17.
  40. Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. *J Clin Endocrinol Metab* 2010;95:1555–65.
  41. Tobeiha M, Moghadasian MH, Amin N, Jafarnejad S. RANKL/RANK/OPG Pathway: a mechanism involved in exercise-induced bone remodeling. *BioMed Res Int* 2020;2020:6910312.
  42. Hanley DA, Adachi JD, Bell A, Brown V. Denosumab: mechanism of action and clinical outcomes. *Int J Clin Pract* 2012;66:1139–46.
  43. Choi NK, Solomon DH, Tsacogianis TN, Landon JE, Song HJ, Kim SC. Comparative safety and effectiveness of denosumab versus zoledronic acid in patients with osteoporosis: a cohort study. *J Bone Miner Res* 2017;32:611–7.
  44. Son S, Oh MY, Yoo BR, Park HB. Comparison of the efficacy of zoledronate and denosumab in patients with acute osteoporotic vertebral compression fractures: a randomized controlled trial. *J Clin Med* 2024;13:2040.
  45. Gibiansky L, Sutjandra L, Doshi S, et al. Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. *Clin Pharmacokinet* 2012;51:247–60.
  46. Brown JP, Dempster DW, Ding B, et al. Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study. *J Bone Miner Res* 2011;26:2737–44.
  47. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. *Bone* 2008;43:222–9.
  48. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. *J Clin Endocrinol Metab* 2011;96:972–80.
  49. Peng J, Wang H, Liu Z, et al. Real-world study of antiresorptive-related osteonecrosis of jaw based on the US

- food and drug administration adverse event reporting system database. *Front Pharmacol* 2022;13:1017391.
50. Kim JW, Kwak MK, Han JJ, et al. Medication related osteonecrosis of the jaw: 2021 position statement of the Korean society for bone and mineral Research and the Korean association of oral and maxillofacial Surgeons. *J Bone Metab* 2021; 28:279–96.
  51. Liu FC, Luk KC, Chen YC. Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan. *Osteoporos Int* 2023;34:1729–37.
  52. Lo JC, O’Ryan FS, Gordon NP, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. *J Oral Maxillofac Surg* 2010;68:243–53.
  53. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. *Lancet Diabetes Endocrinol* 2017;5:513–23.
  54. Tsuchiya K, Ishikawa K, Kudo Y, et al. Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: a prospective cohort study. *BoneKEy Rep* 2021; 14:101090.
  55. Hellstein JW, Adler RA, Edwards B, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American Dental Association Council on Scientific Affairs. *J Am Dent Assoc* 2011;142:1243–51.
  56. Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetic/s/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. *Clin Pharmacokinet* 2005;44:551–70.
  57. Sutjandra L, Rodriguez RD, Doshi S, et al. Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. *Clin Pharmacokinet* 2011;50:793–807.
  58. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. *Bone* 1996;18:75–85.
  59. Landesberg R, Cozin M, Cremers S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. *J Oral Maxillofac Surg* 2008;66:839–47.
  60. Yamashita J, Koi K, Yang DY, McCauley LK. Effect of zoledronate on oral wound healing in rats. *Clin Cancer Res* 2011;17: 1405–14.
  61. Kobayashi Y, Hiraga T, Ueda A, et al. Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice. *J Bone Miner Metabol* 2010; 28:165–75.
  62. Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. *Lancet* 2009;373:1253–63.
  63. Wei LY, Cheng YW, Chiu WY, et al. Risk factors influencing medication-related osteonecrosis of the jaws (MRONJ) following dental extraction among osteoporotic patients in Taiwan. *Head Neck* 2024 (in press).
  64. Barrett J, Worth E, Bauss F, Epstein S. Ibandronate: a clinical pharmacological and pharmacokinetic update. *J Clin Pharmacol* 2004;44:951–65.
  65. Migliorati CA, Armonis BN, Nicolatou-Galitis O. Oral osteonecrosis associated with the use of ibandronate: report of a case and clinical implications. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2008;106:e18–21.
  66. Notarnicola A, Lisi S, Sisto M, De Marino AV, D’Amore M. Possible role of oral ibandronate administration in Osteonecrosis of the Jaw: a case report. *Int J Immunopathol Pharmacol* 2012;25:311–6.
  67. Rastogi A, Rattan V, Bhadada SK. Osteonecrosis of jaw associated with bisphosphonate use. *Indian J Endocrinol Metab* 2012;16:450–2.
  68. Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B. Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. *J Clin Endocrinol Metab* 2017;102:354–8.
  69. Aubry-Rozier B, Gonzalez-Rodriguez E, Stoll D, Lamy O. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports. *Osteoporos Int* 2016;27: 1923–5.
  70. Reid IR, Billington EO. Drug therapy for osteoporosis in older adults. *Lancet* 2022;399:1080–92.
  71. Muchmore DB. Raloxifene: a selective estrogen receptor modulator (SERM) with multiple target system effects. *Oncologist* 2000;5:388–92.
  72. Clemett D, Spencer CM. Raloxifene: a review of its use in postmenopausal osteoporosis. *Drugs* 2000;60:379–411.
  73. Johnston Jr CC, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. *Arch Intern Med* 2000;160:3444–50.
  74. Taranta A, Brama M, Teti A, et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. *Bone* 2002;30:368–76.
  75. Pontes HAR, Souza LL, Uchôa DCC, Cerqueira JMM. Mandibular osteonecrosis associated with raloxifene. *J Craniofac Surg* 2018;29:e257–9.
  76. Chiu WY, Chien JY, Yang WS, Juang JM, Lee JJ, Tsai KS. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene. *J Clin Endocrinol Metab* 2014;99:2729–35.
  77. Bodenner D, Redman C, Riggs A. Teriparatide in the management of osteoporosis. *Clin Interv Aging* 2007;2: 499–507.
  78. Kuchler U, Luvizuto ER, Tangl S, Watzek G, Gruber R. Short-term teriparatide delivery and osseointegration: a clinical feasibility study. *J Dent Res* 2011;90:1001–6.
  79. de Oliveira Puttini I, Gomes-Ferreira P, de Oliveira D, Hassumi JS, Gonçalves PZ, Okamoto R. Teriparatide improves alveolar bone modelling after tooth extraction in orchietomized rats. *Arch Oral Biol* 2019;102:147–54.
  80. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. *N Engl J Med* 2016;375:1532–43.
  81. Kobayakawa T, Miyazaki A, Saito M, Suzuki T, Takahashi J, Nakamura Y. Denosumab versus romosozumab for postmenopausal osteoporosis treatment. *Sci Rep* 2021;11:11801.
  82. Lim SY, Bolster MB. Profile of romosozumab and its potential in the management of osteoporosis. *Drug Des Dev Ther* 2017; 11:1221–31.
  83. Baron R, Gori F. Targeting WNT signaling in the treatment of osteoporosis. *Curr Opin Pharmacol* 2018;40:134–41.
  84. Lyu H, Zhao SS, Yoshida K, et al. Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use. *J Clin Endocrinol Metab* 2019;104: 5611–20.
  85. Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, et al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. *J Bone Miner Res* 2019;34:419–28.
  86. Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. *Lancet* 2013;382: 50–6.

87. Loyson T, Van Cann T, Schöffski P, et al. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. *Acta Clin Belg* 2018;73:100–9.
88. Esposito M, Grusovin MG, Maghaireh H, Worthington HV. Interventions for replacing missing teeth: different times for loading dental implants. *Cochrane Database Syst Rev* 2013;2013:Cd003878.
89. Trombelli L, Farina R, Marzola A, Bozzi L, Liljenberg B, Lindhe J. Modeling and remodeling of human extraction sockets. *J Clin Periodontol* 2008;35:630–9.
90. Mustakim KR, Eo MY, Lee JY, Seo MH, Kim SM. Clinical significance of drug cessation on medication-related osteonecrosis of the jaw in patients with osteoporosis. *J Korean Assoc Oral Maxillofac Surg* 2023;49:75–85.
91. Muska E, Walter C, Knight A, et al. Atraumatic vertical tooth extraction: a proof of principle clinical study of a novel system. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2013;116:e303–10.
92. Matsumoto A, Sasaki M, Schmelzeisen R, Oyama Y, Mori Y, Voss PJ. Primary wound closure after tooth extraction for prevention of medication-related osteonecrosis of the jaw in patients under denosumab. *Clin Oral Invest* 2017;21:127–34.
93. Okuma K, Hirano S, Hayakawa I. Occlusal pressure pattern analysis of complete dentures for evaluation of occlusal adjustment. *J Med Dent Sci* 2004;51:197–203.
94. Jainkittivong A, Aneksuk V, Langlais RP. Oral mucosal conditions in elderly dental patients. *Oral Dis* 2002;8:218–23.
95. Medsinghe SV, Kohad R, Budhiraja H, Singh A, Gurha S, Sharma A. Buccal exostosis: a rare entity. *J Int Oral Health* 2015;7:62–4.
96. Schiødt M. Mandibular and palatal tori exposed by trauma are risk factors for medication-related osteonecrosis of the jaws: a report from the Copenhagen ONJ cohort. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2020;129:e193.
97. Ueda N, Aoki K, Shimotsuji H, et al. Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer. *J Bone Miner Metabol* 2021;39:623–30.
98. Bedogni A, Mauceri R, Fusco V, et al. Italian position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ). *Oral Dis* 2024;30:3679–709.
99. Kiho K, Sumitomo S, Tanaka M, et al. Pulpal disease arising from medication-related osteonecrosis of the jaw: a case report. *J Endod* 2020;46:1149–54.
100. Cardoso CL, Barros CA, Curra C, et al. Radiographic findings in patients with medication-related osteonecrosis of the jaw. *Int J Dent* 2017;2017:3190301.
101. Kim JE, Yoo S, Choi SC. Several issues regarding the diagnostic imaging of medication-related osteonecrosis of the jaw. *Imaging Sci Dent* 2020;50:273–9.